Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.
about
Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications.Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin BThe utility of metabolomics in natural product and biomarker characterization.Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II studyMarine Peptides: Bioactivities and ApplicationsCrude Extracts of Marine-derived and Soil Fungi of the Genus Neosartorya Exhibit Selective Anticancer Activity by Inducing Cell Death in Colon, Breast and Skin Cancer Cell Lines.Marine-derived angiogenesis inhibitors for cancer therapy.Plitidepsin: design, development, and potential place in therapy.Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.Investigational drugs for T-cell lymphoma.Antitumor bioactive peptides isolated from marine organisms.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
Q33612302-29FA56DA-942A-41B0-8208-7F7B0F49B0B0Q35244917-2B659E3E-D145-4F0D-898D-9C6A47187059Q35612950-55685D07-B4DA-41F7-BB48-34F490420669Q35762668-C8ED7C5D-CDDB-457F-9231-8BC7D4C16440Q35775249-8B65FAFD-23C6-4424-AB82-BED78E43CD41Q35890691-E64B001D-90FA-4086-B817-1EFB5EFE3918Q36580480-4D48CB1A-545C-41BD-A5C1-A938992E7A6BQ36994177-59138E25-D7E0-40F1-8643-3DD346A1D679Q37603607-6558749C-8291-4A73-8A3E-9F4D2F54E642Q38113568-69C0ED09-D09E-4DF4-A509-1ECE153015D6Q38260926-56F1A740-0989-4176-B5E5-950D5C0E5756Q38289038-6B3D3960-4E80-40C3-8990-59628B0648A0Q38635909-42BE9614-76D7-4F05-97B5-075D12078A6AQ38663010-03F53CD7-41E0-42DA-BEEA-285C0D4A062EQ38782072-5E9A6FC9-4181-42BC-BB99-41E2EDC27B31Q39305333-BD207A85-E93D-42DF-9107-3184889692EDQ50218409-3B04B188-2CBD-4DD6-A8FF-BCC3014C4B67Q52646693-852F9245-9219-49F9-8180-6B4300D8B661Q55365628-47723571-DCF9-4D9A-A5DC-7235DE82BDA4
P2860
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@ast
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@en
type
label
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@ast
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@en
prefLabel
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@ast
Multicenter phase II study of ...... actory non-Hodgkin's lymphoma.
@en
P2093
P2860
P50
P1433
P1476
Multicenter phase II study of ...... ractory non-Hodgkin's lymphoma
@en
P2093
Alessandro M Gianni
Bernardo de Miguel
Carmen Kahatt
Christian Gisselbrecht
Christophe Fermé
Claudia Corrado
Dolores Caballero
Franco Cavalli
Martin Cullell-Young
Reyes Arranz
P2860
P304
P356
10.3324/HAEMATOL.2012.069757
P577
2012-10-12T00:00:00Z